Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit is substantial in the second-line treatment of ALK+ advanced non-small cell lung cancer (NSCLC). |
Clinical Added Value
| moderate |
XALKORI provides a moderate improvement in actual benefit (level III) in the treatment strategy of ALK+ advanced non-small cell lung cancer as a second-line therapy and compared with docetaxel or pemetrexed. |
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
y5HVTfMh51JF8vUC
